Cochleovestibular toxicity induced by immune checkpoint inhibition: a case series

Eur J Cancer. 2019 Aug:117:116-118. doi: 10.1016/j.ejca.2019.05.022. Epub 2019 Jul 3.

¹ Dermatology, AP-HP Hopital Saint-Louis, Paris, France.
² Neuro-Oncology, AP-HP Hopital Saint-Louis, Paris, France; Université de Paris, France.
³ Medical Oncology, AP-HP Hopital Saint-Louis, Paris, France.
⁴ Thoracic Oncology, AP-HP Hopital Bichat, Paris, France.
⁵ Dermatology, AP-HP Hopital Saint-Louis, Paris, France; Université de Paris, INSERM HIPI, France.
⁶ Department of Otorhinolaryngology, Head & Neck Surgery, Hopital Lariboisière, Paris, France.
⁷ Dermatology, AP-HP Hopital Saint-Louis, Paris, France; Université de Paris, INSERM HIPI, France. Electronic address: julie.delyon@aphp.fr.

No abstract available

Keywords: Anti-PD1; Cochleovestibular toxicity; Immune checkpoint inhibitors; Immune-related adverse events.

Publication types